- Details
- Medical Oncologist and member of the scientific committee of the upcoming European International Kidney Cancer Symposium, Samra Turajlic joins Rana McKay to discuss the upcoming IKCS meeting being held April 22nd through the 24th in Antwerpen, Belgium. The program will consist of Award Lectures in Urology and Oncology, Basic Science in renal cell carcinoma (RCC), Biomarkers in RCC, Diagnostics, an...
|
- Details
- Alicia Morgans is joined by Toni Choueiri to discuss his GU ASCO 2022 presentation on a 30-month follow-up from the KEYNOTE-564 trial of post-nephrectomy adjuvant pembrolizumab in patients with renal cell carcinoma (RCC). Dr. Choueiri highlights that adjuvant pembrolizumab continued to demonstrate a disease-free survival (DFS) benefit following nephrectomy for patients with intermediate-high or hi...
|
- Details
- Alicia Morgans, MD, MPH, and Thomas Powles, MBBS, MRCP, MD, discuss the recent ASCO presentation on 42 -month follow-up from the KEYNOTE-426 study. The KEYNOTE-426 study is a randomized phase three study looking at combination therapies of axitinib and pembrolizumab versus sunitinib, in metastatic kidney cancer. Biographies: Thomas Powles, MBBS, MRCP, MD, Professor of Genitourinary Oncology, Lead...
|
- Details
- At the 2021 ASCO GU Cancers Symposium, Dr Robert Motzer and colleagues presented the results of the CLEAR study examining first-line lenvatinib and everolimus or lenvatinib and pembrolizumab versus sunitinib in patients with advanced renal cell carcinoma and concurrent with the presentation, CLEAR was published in the New England Journal of Medicine. In this UroToday Journal Club, Christopher Wall...
|
- Details
- In this conversation, Rana McKay and Andrea Apolo highlight several studies presented during the ASCO 2021 Annual Meeting on combination therapeutic options for advanced renal cell carcinoma (RCC). Dr. Apolo expands on several studies she highlighted in her presentation and where these treatment options fit into the treatment landscape of advanced RCC potentially enhancing the immune effect of imm...
|
- Details
- Following the Presidential Symposium presentation at the European Society of Medical Oncology (ESMO) 2020 Virtual Annual Meeting, Toni Choueiri, MD, joins Alicia Morgans, MD, MPH and discusses the CheckMate—9ER phase III, open-label, international randomized controlled trial among patients with previously untreated, histologically confirmed advanced or metastatic renal cell carcinoma with a clear...
|
- Details
- Alicia Morgans, MD, MPH, welcomes Bradley McGregor, MD, to discuss the use of an antibody-drug conjugate for frontline kidney cancer treatment. Dr. McGregor gives insight into a unique target, TIM-1, strategically expressed on renal cell carcinoma but not in healthy kidney tissue. He describes a phase 1 study that assessed the dosage for the antibody-drug conjugate. The TIM-1 target requires furth...
|
- Details
- The development of novel combination therapies in kidney cancer is on the rise due to the approval of combination immunotherapies. Joining Alicia Morgans is Chung-Han (Joe) Lee, who highlights his recent advancements in TKI-IO combination therapies. Dr. Lee also concentrates on the responses of biomarkers with aims to aid in personalized treatment for kidney cancer patients, especially those for n...
|
- Details
- Following presentations at the ASCO 2020 Virtual Annual Meeting, Toni Choueiri, MD, discusses the SAVOIR, COSMIC-313, and OMNIVORE kidney cancer studies. COSMIC-313 is a phase III study of cabozantinib in combination with nivolumab and ipilimumab in patients with untreated advanced renal cell carcinoma. The phase II OMNIVORE study enrolled patients with advanced RCC and no prior checkpoint inhibit...
|
- Details
- Clear cell renal carcinoma has a modest tumor mutational burden and increased infiltration of CD8+ T cells which is associated with worse prognosis in this disease. Biomarkers for response to immune checkpoint inhibitors are needed to predict which patients will respond. David Braun joins Alicia Morgans and overviews his ASCO 2020 presentation on the genomic and immune determinants of response to...
|
